NCT07092306尚未招募2 期
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
Tang Xiaodong0 个研究点目标入组 74 人开始时间: 2025年8月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 74
- 主要终点
- Objective Response Rate，ORR
研究概览
简要总结
This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio. After enrollment, patients will receive either irinotecan liposomal injection combined with temozolomide and vincristine or irinotecan injection combined with temozolomide and vincristine. The aim is to evaluate the efficacy, safety, and impact on quality of life of the irinotecan liposomal combination regimen compared to the irinotecan injection combined with temozolomide and vincristine in the treatment of advanced Ewing's sarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject or their legal representative must sign the written informed consent before enrollment.
- •Age ≥ 8 years and ≤ 40 years, both male and female are eligible.
- •Pathologically confirmed Ewing's sarcoma, and detailed pathological reports must be provided. Pathology must be confirmed by fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) to show the presence of Ewing's sarcoma-specific FET family (including EWSR1 or FUS) gene breaks. This study does not impose special restrictions on fusion partner genes, but clear FET-non ETS fusions (such as EWSR1-WT1, EWSR1-NFATC2, EWSR1-PATZ1, etc.) do not meet the enrollment criteria.
- •At least one measurable target lesion as judged by RECIST 1.1 criteria.
- •Failure of first-line standard treatment. First-line standard treatment includes the following drugs: doxorubicin, cyclophosphamide and/or ifosfamide. Treatment failure is defined as disease progression during adjuvant chemotherapy or within 6 months after chemotherapy. For disease progression more than 6 months after chemotherapy, the consent of the subject or their legal representative is required.
- •ECOG score: 0-
- •Expected survival ≥ 3 months.
- •Recovery from previous treatment: According to NCI-CTCAE 5.0, all side effects (except alopecia) must have subsided to grade 1 or below.
- •Normal major organ function, meeting the following criteria:
- •Blood routine examination must meet the following criteria (no blood transfusion, no use of hematopoietic factors, and no drug correction within 14 days):
- •ANC ≥ 1.5×109/L;
- •HB ≥ 90 g/L;
- •PLT ≥ 100×109/L; 2) Biochemical examination must meet the following criteria:
- •TBIL ≤ 1.5 ULN;
- •ALT, AST ≤ 2.5 ULN (if liver function abnormalities are due to liver metastasis, then ≤ 5 ULN);
- •Serum creatinine sCr ≤ 1.5 ULN, endogenous creatinine clearance rate ≥ 50 ml/min (Cockcroft-Gault formula); 3) Coagulation function must meet the following criteria: INR ≤ 1.5 and APTT ≤ 1.5 ULN.
- •Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within one week before enrollment, with a negative result, and be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug. For men, they must agree to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug or have undergone surgical sterilization.
排除标准
- •Known hypersensitivity, anaphylaxis or intolerance to irinotecan liposome, temozolomide and vincristine or their excipients;
- •Within 2 weeks after the last systemic cytotoxic drug treatment, radiotherapy, targeted therapy or any anti-tumor drug treatment except immunotherapy;
- •Patients who have received irinotecan treatment before;
- •Other malignant tumors within the past 5 years;
- •Known symptomatic central nervous system metastases;
- •Known symptomatic brain metastases, spinal cord compression, carcinomatous meningitis, or unstable brain or leptomeningeal disease found on CT or MRI at screening;
- •Symptomatic serous cavity effusion (including pleural effusion, ascites, pericardial effusion) requiring surgical intervention;
- •Uncontrolled concomitant diseases, including but not limited to: poorly controlled hypertension, heart failure, diabetes, persistent active infection, poorly controlled active peptic ulcer, or mental disorders or social conditions that may affect the subject's compliance with the study;
- •Abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN + 4s or APTT > 1.5 ULN), with bleeding tendency or receiving thrombolytic or anticoagulant therapy;
- •Treatment with anticoagulants or vitamin K antagonists such as warfarin, heparin or similar drugs; Note: Under the condition of INR ≤ 1.5, low-dose heparin (adult daily dose of 6,000 - 12,000 U), low-dose aspirin (daily dose ≤ 100 mg), or rivaroxaban (daily dose ≤ 10 mg) for preventive purposes is allowed;
- •History of drug abuse of psychotropic drugs and unable to quit or with mental disorders;
- •Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.);
- •Open wounds, fractures, or poorly healing wounds;
- •Major surgery within 2 weeks;
- •Confirmed inflammatory bowel disease, intestinal obstruction or chronic diarrhea;
- •Cavity organ fistula or perforation within 6 months;
- •Active hepatitis B or C virus infection or active infection requiring antimicrobial treatment (such as the use of antibacterial drugs, antiviral drugs, antifungal drugs);
- •Participation in other interventional anti-tumor clinical trials within 4 weeks;
- •Patients who have used strong CYP3A4 inducers or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 3 weeks before the first dose;
- •Any condition that the investigator deems may harm the patient or prevent the patient from meeting or fulfilling the study requirements.
研究组 & 干预措施
Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)
Experimental
干预措施: Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT) (Drug)
Irinotecan Combined with Temozolomide and Vincristine (VIT)
Active Comparator
干预措施: Irinotecan Combined with Temozolomide and Vincristine (VIT) (Drug)
结局指标
主要结局
Objective Response Rate，ORR
时间窗: 6 weeks
次要结局
- progression free survival，PFS(1 year)
- overall survival，OS(1 year)
研究者
Tang Xiaodong
professor
Peking University People's Hospital
相似试验
Unknown
2 期
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung Cancer (NSCLC)NCT03407300Haining Health-Coming Biotech Co., Ltd.80
尚未招募
不适用
Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLMColorectal Cancer Liver MetastasisNCT06021015Zhongda Hospital72
已完成
不适用
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AMNon-infected Diabetic Foot UlcerDiabetic WoundNon-ischemic Diabetic Foot UlcerDiabetic FootDiabetic Foot UlcerNCT06565156BioStem Technologies72
已完成
不适用
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-ACDiabetic Foot UlcerNCT06511596BioStem Technologies71
Unknown
不适用
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV FistulaArteriovenous FistulaNCT04393688BrosMed Medical Co., Ltd168